Under-enrollment in rare kidney disease trials: lessons learned from the PRIVENT recurrent FSGS [0.03%]
罕见肾脏疾病试验的入组不足:PRIVENT复发性FSGS试验的经验教训
Priya S Verghese,Rasheed Gbadegesin,Hatem Amer et al.
Priya S Verghese et al.
Nans Florens,Mickael Bobot
Nans Florens
Barbara Soler,Daria Abasheva,Alberto Ortiz
Barbara Soler
The main manifestation of wild-type transthyretin amyloidosis (wtATTR) is cardiac disease in the elderly. Kidney involvement is frequently underappreciated and has been dismissed as a functional consequence of heart failure. Amyloidosis cha...
Daratumumab Monotherapy versus Bortezomib-Based Regimens in frail patients with Biopsy-Proven Renal AL Amyloidosis [0.03%]
与来那度胺联合硼替佐米或环磷酰胺相比,达雷妥尤单抗单药治疗接受活检证实的肾AL淀粉样变性虚弱患者疗效更好
Roccatello Dario,Sciascia Savino,Antonella Barreca et al.
Roccatello Dario et al.
Background: Bortezomib-based regimens have long represented the standard option for systemic AL amyloidosis, whereas daratumumab has recently emerged as a promising alternative. We compared two consecutive single-center c...
The use of albuminuria and proteinuria for regulatory clinical decision making: a perspective from European regulators [0.03%]
欧洲监管机构对管理临床决策中使用尿白蛋白和蛋白尿的看法
Frank Holtkamp,Hrefna Gudmundsdottir,Karin Janssen van Doorn et al.
Frank Holtkamp et al.
DUAL GIP/GLP-1Ra reduces residual proteinuria in non-diabetic fabry disease [0.03%]
针对非糖尿病法布雷病患者GLP-1Ra减少蛋白尿残留损害
Eleonora Riccio,Alessandra Cuomo,Ivana Capuano et al.
Eleonora Riccio et al.
Background: Residual proteinuria remains a major determinant of renal disease progression in Fabry disease (FD) despite optimized enzyme replacement or chaperone therapy and maximal renin-angiotensin system (RAS) blockade...
Yang Liu,Yuan Cheng,Di Wu et al.
Yang Liu et al.
Background: Rituximab (RTX) is effective first-line therapy for primary membranous nephropathy (PMN), but some patients respond poorly or develop anti-rituximab antibodies (ARA), leading to treatment failure. Obinutuzumab...
Reconsidering the measurement of urinary proteins in chronic kidney disease: towards a global consensus on albuminuria assessment [0.03%]
慢性肾脏病尿蛋白检测的再评价:迈向全球统一的白蛋白尿评估标准共识
Hiddo J L Heerspink,Bengt Fellstrom,Christoph Wanner et al.
Hiddo J L Heerspink et al.
Kidney biopsy during pregnancy: indications, complications, results and therapeutic impact [0.03%]
孕期肾活检:指征、并发症、结果和治疗影响
Camille Imbert,Gaëlle Guettrot-Imbert,Julie Bruno et al.
Camille Imbert et al.
Background and hypothesis: The diagnosis of kidney disease can be challenging during pregnancy. A kidney biopsy (KB) may be proposed, but there is little recent data available to assess the risk/benefit ratio of this proc...